Company Description

Corstasis Therapeutics is an innovative biopharmaceutical company providing enhanced outpatient therapeutic options for patients with cardiovascular and renal disease. The company’s lead product, ENBUMYST™ (bumetanide nasal spray), is the first FDA-approved intranasal loop diuretic, and Corstasis is developing a near term pipeline of subcutaneous diuretic products.